OncoResponse Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 35

Employees
  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $50M

  • Investors
  • 24

OncoResponse General Information

Description

Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, enabling doctors and patients to optimally combat cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
  • 1124 Columbia Street
  • Suite 300
  • Seattle, WA 98104
  • United States
+1 (206) 000-0000

OncoResponse Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoResponse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Debt - General 08-Feb-2022 $50M 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 25-Mar-2021 000.00 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 14-Jun-2019 0000 000.00 0000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 23-Mar-2017 $29.5M $29.5M 0000 Completed Pre-Clinical Trials
1. Joint Venture 18-Aug-2015 Completed Startup
To view OncoResponse’s complete valuation and funding history, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 29,499,000 $0.001000 $0.06 $1 $1 1x $1 20.32%
To view OncoResponse’s complete cap table history, request access »

OncoResponse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer
Drug Discovery
Seattle, WA
35 As of 2023
00000
000000000 00000

0000 0

strud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Austin, TX
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoResponse Competitors (122)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Austin, TX 00 00000 00000000000 00000
000000-000 0000000 Venture Capital-Backed Palo Alto, CA 00 00000 00000000000 00000
00000000 000000000 Venture Capital-Backed Pasadena, CA 0 00.000 000000000 00.000
000000 00000000000 Venture Capital-Backed Plymouth Meeting, PA 00 000.00 00000000000 000.00
You’re viewing 5 of 122 competitors. Get the full list »

OncoResponse Patents

OncoResponse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210047424-A1 Immunomodulatory antibodies and methods of use thereof Active 19-Jul-2019 00000000000
US-11034770-B2 Immunomodulatory antibodies and methods of use thereof Active 19-Jul-2019 00000000000
US-20220289861-A1 Immunomodulatory antibodies and methods of use thereof Pending 19-Jul-2019 00000000000
US-20210253733-A1 Immunomodulatory antibodies and methods of use thereof Pending 19-Jul-2019 00000000000
AU-2020315878-A1 Immunomodulatory antibodies and methods of use thereof Pending 19-Jul-2019 C07K16/2896
To view OncoResponse’s complete patent history, request access »

OncoResponse Executive Team (7)

Name Title Board Seat Contact Info
Clifford Stocks Co-Founder, Chief Executive Officer & Board Member
Christopher Russell Chief Financial Officer
Kamal Puri Chief Scientific Officer
Robert Lechleider MD Chief Medical Officer
You’re viewing 4 of 7 executive team members. Get the full list »

OncoResponse Board Members (14)

Name Representing Role Since
Clifford Stocks OncoResponse Co-Founder, Chief Executive Officer & Board Member 000 0000
Daguang Wang Ph.D Yonjin Venture Board Member 000 0000
David DeNardo Ph.D OncoResponse scientific advisor 000 0000
John Mckearn Ph.D RiverVest Venture Partners Board Member 000 0000
Miriam Merad Ph.D OncoResponse scientific advisor 000 0000
You’re viewing 5 of 14 board members. Get the full list »

OncoResponse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoResponse Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bering Capital Venture Capital Minority 000 0000 000000 0
InterVest Venture Capital Minority 000 0000 000000 0
Magnetar Capital Hedge Fund Minority 000 0000 000000 0
Reimagined Ventures Family Office Minority 000 0000 000000 0
Yonjin Venture Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »

OncoResponse Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 07-Nov-2017 0000000000 Biotechnology 00000000
To view OncoResponse’s complete acquisitions history, request access »